{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:15:55Z","timestamp":1789146955927,"version":"build-2803163510"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Saudi Pharm. J."],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s44446-025-00056-w","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T09:03:26Z","timestamp":1768208606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeting the PI3K\/AKT\/mTOR signaling pathway in prostate cancer: Molecular dysregulation, therapeutic advances, and future directions"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0157-9240","authenticated-orcid":false,"given":"Saad","family":"Alobid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"56_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/modpathol.2010.208","volume":"24","author":"L Agell","year":"2011","unstructured":"Agell L, Hern\u00e1ndez S, Salido M, de Muga S, Juanpere N, Arum\u00ed-Uria M et al (2011) PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Mod Pathol 24:443\u2013452. https:\/\/doi.org\/10.1038\/modpathol.2010.208","journal-title":"Mod Pathol"},{"key":"56_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/srep18137","volume":"5","author":"M Allegretti","year":"2015","unstructured":"Allegretti M, Ricciardi MR, Licchetta R, Mirabilii S, Orecchioni S, Reggiani F et al (2015) The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. Sci Rep 5:18137. https:\/\/doi.org\/10.1038\/srep18137","journal-title":"Sci Rep"},{"key":"56_CR3","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1158\/1078-0432.CCR-10-2285","volume":"17","author":"JK Altman","year":"2011","unstructured":"Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ et al (2011) Dual mTORC2\/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 17:4378\u20134388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2285","journal-title":"Clin Cancer Res"},{"key":"56_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104270","volume":"145","author":"A Alwhaibi","year":"2019","unstructured":"Alwhaibi A, Verma A, Adil MS, Somanath PR (2019) The unconventional role of Akt1 in the advanced cancers and in diabetes-promoted carcinogenesis. Pharmacol Res 145:104270. https:\/\/doi.org\/10.1016\/j.phrs.2019.104270","journal-title":"Pharmacol Res"},{"key":"56_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/COC.0000000000000852","volume":"44","author":"M Amin","year":"2021","unstructured":"Amin M, Gao F, Terrero G, Picus J, Wang-Gillam A, Suresh R et al (2021) Phase I study of docetaxel and temsirolimus in refractory solid tumors. Am J Clin Oncol 44:443\u2013448. https:\/\/doi.org\/10.1097\/COC.0000000000000852","journal-title":"Am J Clin Oncol"},{"key":"56_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.breast.2022.03.018","volume":"63","author":"A Andrikopoulou","year":"2022","unstructured":"Andrikopoulou A, Chatzinikolaou S, Panourgias E, Kaparelou M, Liontos M, Dimopoulos M-A et al (2022) The emerging role of capivasertib in breast cancer. Breast 63:157\u2013167. https:\/\/doi.org\/10.1016\/j.breast.2022.03.018","journal-title":"Breast"},{"key":"56_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2017.02.030","volume":"81","author":"AJ Armstrong","year":"2017","unstructured":"Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J et al (2017) Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. Eur J Cancer 81:228\u2013236. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.030","journal-title":"Eur J Cancer"},{"key":"56_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","volume":"387","author":"G Attard","year":"2016","unstructured":"Attard G, Parker C, Eeles RA, Schr\u00f6der F, Tomlins SA, Tannock I et al (2016) Prostate cancer. Lancet 387:70\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(14)61947-4","journal-title":"Lancet"},{"key":"56_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0165-3","volume":"50","author":"M-O Baek","year":"2018","unstructured":"Baek M-O, Song H-I, Han J-S, Yoon M-S (2018) Differential regulation of mTORC1 and mTORC2 is critical for 8-Br-cAMP-induced decidualization. Exp Mol Med 50:1\u201311. https:\/\/doi.org\/10.1038\/s12276-018-0165-3","journal-title":"Exp Mol Med"},{"key":"56_CR10","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","volume":"18","author":"J Baselga","year":"2017","unstructured":"Baselga J, Im S-A, Iwata H, Cort\u00e9s J, De Laurentiis M, Jiang Z et al (2017) Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18:904\u2013916. https:\/\/doi.org\/10.1016\/S1470-2045(17)30376-5","journal-title":"Lancet Oncol"},{"key":"56_CR11","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/1535-7163.MCT-10-1099","volume":"10","author":"VS Bhagwat","year":"2011","unstructured":"Bhagwat VS, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C et al (2011) Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther 10:1394\u20131406. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-1099","journal-title":"Mol Cancer Ther"},{"key":"56_CR12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N (2023) PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer 129:904\u2013916. https:\/\/doi.org\/10.1038\/s41416-023-02326-7","journal-title":"Br J Cancer"},{"key":"56_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41568-024-00708-4","volume":"24","author":"A Boire","year":"2024","unstructured":"Boire A, Burke K, Cox TR, Guise T, Jamal-Hanjani M, Janowitz T et al (2024) Why do patients with cancer die? Nat Rev Cancer 24:578\u2013589. https:\/\/doi.org\/10.1038\/s41568-024-00708-4","journal-title":"Nat Rev Cancer"},{"key":"56_CR14","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.3390\/cancers14225520","volume":"14","author":"A Bouyahya","year":"2022","unstructured":"Bouyahya A, El Allam A, Aboulaghras S, Bakrim S, El Menyiy N, Alshahrani MM et al (2022) Targeting mTOR as a cancer therapy: recent advances in natural bioactive compounds and immunotherapy. Cancers (Basel) 14:5520. https:\/\/doi.org\/10.3390\/cancers14225520","journal-title":"Cancers (Basel)"},{"key":"56_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2020.118731","volume":"1867","author":"L Braglia","year":"2020","unstructured":"Braglia L, Zavatti M, Vinceti M, Martelli AM, Marmiroli S (2020) Deregulated PTEN\/PI3K\/AKT\/mTOR signaling in prostate cancer: still a potential druggable target? Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research 1867:118731. https:\/\/doi.org\/10.1016\/j.bbamcr.2020.118731","journal-title":"Biochimica Et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"56_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"56_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.04.001","volume":"84","author":"MN Brook","year":"2023","unstructured":"Brook MN, N\u00ed Raghallaigh H, Kote-Jarai Z, Eeles RA (2023) Reply to Kari Hemminki, Jianguang Ji, and Jan Sundquist\u2019s letter to the editor re: Mark N. Brook, Holly N\u00ed Raghallaigh, Koveela Govindasami, et al. Family history of prostate cancer and survival outcomes in the UK genetic prostate cancer study. Eur Urol 2023;83:257\u201366. Eur Urol 84:e15. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.001","journal-title":"Eur Urol"},{"key":"56_CR18","first-page":"2850","volume":"12","author":"L Buckingham","year":"2022","unstructured":"Buckingham L, Hao T, O\u2019Donnell J, Zhao Z, Zhang X, Fan Y et al (2022) Ipatasertib, an oral AKT inhibitor, inhibits cell proliferation and migration, and induces apoptosis in serous endometrial cancer. Am J Cancer Res 12:2850\u20132862","journal-title":"Am J Cancer Res"},{"key":"56_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/07853890.2023.2177883","volume":"55","author":"WC Burkett","year":"2023","unstructured":"Burkett WC, Zhao Z, Newton MA, Sun W, Deng B, Secord AA et al (2023) Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma. Ann Med 55:603\u2013614. https:\/\/doi.org\/10.1080\/07853890.2023.2177883","journal-title":"Ann Med"},{"key":"56_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","volume":"19","author":"BS Carver","year":"2011","unstructured":"Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S et al (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575\u2013586. https:\/\/doi.org\/10.1016\/j.ccr.2011.04.008","journal-title":"Cancer Cell"},{"key":"56_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/TCRM.S251668","volume":"17","author":"D-Y Chang","year":"2021","unstructured":"Chang D-Y, Ma W-L, Lu Y-S (2021) Role of Alpelisib in the treatment of PIK3CA-mutated breast cancer: patient selection and clinical perspectives. Ther Clin Risk Manag 17:193\u2013207. https:\/\/doi.org\/10.2147\/TCRM.S251668","journal-title":"Ther Clin Risk Manag"},{"key":"56_CR22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/modpathol.2012.104","volume":"25","author":"A Chaux","year":"2012","unstructured":"Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J et al (2012) Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol 25:1543\u20131549. https:\/\/doi.org\/10.1038\/modpathol.2012.104","journal-title":"Mod Pathol"},{"key":"56_CR23","doi-asserted-by":"publisher","first-page":"CT161","DOI":"10.1158\/1538-7445.AM2018-CT161","volume":"78","author":"Z Chen","year":"2018","unstructured":"Chen Z, Qiu Y (2018) Abstract CT161: Clinical study of PD-1 inhibitor with mTOR inhibitor for relapsed and refractory brain tumors. Cancer Res 78:CT161\u2013CT161. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-CT161","journal-title":"Cancer Res"},{"key":"56_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33\u201339. https:\/\/doi.org\/10.1038\/nm972","journal-title":"Nat Med"},{"key":"56_CR25","doi-asserted-by":"publisher","unstructured":"Chia SKL, Redfern AD, Ayoub J-PM, Chalchal HI, Rayson D, Rushton M, et al. (2025) A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4\/6 inhibitor and aromatase inhibitor: The CCTG\/BCT MA.40\/FINER study (NCT04650581). J Clin Oncol. 43. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA1005","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1005"},{"key":"56_CR26","doi-asserted-by":"publisher","unstructured":"Choudhury AD. (2022) PTEN\u2010PI3K pathway alterations in advanced prostate cancer and clinical implications. Prostate. 82. https:\/\/doi.org\/10.1002\/pros.24372","DOI":"10.1002\/pros.24372"},{"key":"56_CR27","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/oncolo\/oyac192","volume":"27","author":"TK Choueiri","year":"2022","unstructured":"Choueiri TK, Porta C, Su\u00e1rez C, Hainsworth J, Voog E, Duran I et al (2022) Randomized phase II trial of sapanisertib \u00b1 TAK-117 vs. everolimus in patients with advanced renal cell carcinoma after VEGF-targeted therapy. Oncologist 27:1048\u20131057. https:\/\/doi.org\/10.1093\/oncolo\/oyac192","journal-title":"Oncologist"},{"key":"56_CR28","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/cncr.29927","volume":"122","author":"H Chow","year":"2016","unstructured":"Chow H, Ghosh PM, de White Vere R, Evans CP, Dall\u2019 Era MA, Yap SA et al (2016) A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer 122:1897\u2013904. https:\/\/doi.org\/10.1002\/cncr.29927","journal-title":"Cancer"},{"key":"56_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6877","author":"N Coleman","year":"2024","unstructured":"Coleman N, Stephen B, Fu S, Karp D, Subbiah V, Ahnert JR et al (2024) Phase I study of sapanisertib (CB-228\/TAK-228\/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.6877","journal-title":"Cancer Med"},{"key":"56_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003402","volume":"10","author":"NB Collins","year":"2022","unstructured":"Collins NB, Al Abosy R, Miller BC, Bi K, Zhao Q, Quigley M et al (2022) PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. J Immunother Cancer 10:e003402. https:\/\/doi.org\/10.1136\/jitc-2021-003402","journal-title":"J Immunother Cancer"},{"key":"56_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.clgc.2014.08.007","volume":"13","author":"KD Courtney","year":"2015","unstructured":"Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT et al (2015) A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 13:113\u2013123. https:\/\/doi.org\/10.1016\/j.clgc.2014.08.007","journal-title":"Clin Genitourin Cancer"},{"key":"56_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A et al (2019) Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis 22:24\u201338. https:\/\/doi.org\/10.1038\/s41391-018-0079-0","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"56_CR33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A (2020) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77:38\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.005","journal-title":"Eur Urol"},{"key":"56_CR34","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1016\/S1470-2045(14)70211-6","volume":"15","author":"J Cuzick","year":"2014","unstructured":"Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z et al (2014) Prevention and early detection of prostate cancer. Lancet Oncol 15:e484\u2013e492. https:\/\/doi.org\/10.1016\/S1470-2045(14)70211-6","journal-title":"Lancet Oncol"},{"key":"56_CR35","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","volume":"25","author":"JS de Bono","year":"2019","unstructured":"de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A et al (2019) Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clin Cancer Res 25:928\u2013936. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0981","journal-title":"Clin Cancer Res"},{"key":"56_CR36","doi-asserted-by":"publisher","first-page":"TPS1109","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1109","volume":"40","author":"M De Laurentiis","year":"2022","unstructured":"De Laurentiis M, Costa L, Gligorov J, Knop A, Senkus-Konefka E, Garc\u00eda-S\u00e1enz JA et al (2022) EPIK-B5: a phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA -mutated advanced breast cancer (ABC) progressing on\/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4\/6 inhibitor (CDK4\/6i). J Clin Oncol 40:TPS1109\u2013TPS1109. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS1109","journal-title":"J Clin Oncol"},{"key":"56_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10549-021-06143-5","volume":"189","author":"R Dent","year":"2021","unstructured":"Dent R, Oliveira M, Isakoff SJ, Im S-A, Espi\u00e9 M, Blau S et al (2021) Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced\/metastatic triple-negative breast cancer. Breast Cancer Res Treat 189:377\u2013386. https:\/\/doi.org\/10.1007\/s10549-021-06143-5","journal-title":"Breast Cancer Res Treat"},{"key":"56_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/1389450114666140106100909","volume":"15","author":"L Dillon","year":"2014","unstructured":"Dillon L, Miller T (2014) Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets 15:65\u201379. https:\/\/doi.org\/10.2174\/1389450114666140106100909","journal-title":"Curr Drug Targets"},{"key":"56_CR39","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4103\/1008-682X.122876","volume":"16","author":"M Edlind","year":"2014","unstructured":"Edlind M, Hsieh A (2014) PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl 16:378. https:\/\/doi.org\/10.4103\/1008-682X.122876","journal-title":"Asian J Androl"},{"key":"56_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.path.2024.10.003","volume":"18","author":"GN Fanelli","year":"2025","unstructured":"Fanelli GN, Nuzzo PV, Pederzoli F, Loda M (2025) Deciphering complexity. Surg Pathol Clin 18:25\u201339. https:\/\/doi.org\/10.1016\/j.path.2024.10.003","journal-title":"Surg Pathol Clin"},{"key":"56_CR41","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1200\/JCO.2018.36.15_suppl.1040","volume":"36","author":"A Forero-Torres","year":"2018","unstructured":"Forero-Torres A, Han H, Dees EC, Wesolowski R, Bardia A, Kabos P et al (2018) Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009). J Clin Oncol 36:1040\u20131040. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.1040","journal-title":"J Clin Oncol"},{"key":"56_CR42","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.cell.2013.04.031","volume":"153","author":"R Fritsch","year":"2013","unstructured":"Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS et al (2013) RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms. Cell 153:1050\u20131063. https:\/\/doi.org\/10.1016\/j.cell.2013.04.031","journal-title":"Cell"},{"key":"56_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4161\/epi.5.2.10778","volume":"5","author":"L Gao","year":"2010","unstructured":"Gao L, Alumkal J (2010) Epigenetic regulation of androgen receptor signaling in prostate cancer. Epigenetics 5:100\u2013104. https:\/\/doi.org\/10.4161\/epi.5.2.10778","journal-title":"Epigenetics"},{"key":"56_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.canlet.2017.05.028","volume":"402","author":"F Gao","year":"2017","unstructured":"Gao F, Alwhaibi A, Sabbineni H, Verma A, Eldahshan W, Somanath PR (2017) Suppression of Akt1-\u03b2-catenin pathway in advanced prostate cancer promotes TGF\u03b21-mediated epithelial to mesenchymal transition and metastasis. Cancer Lett 402:177\u2013189. https:\/\/doi.org\/10.1016\/j.canlet.2017.05.028","journal-title":"Cancer Lett"},{"key":"56_CR45","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH et al (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22:138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6","journal-title":"Mol Cancer"},{"key":"56_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6:425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5","journal-title":"Signal Transduct Target Ther"},{"key":"56_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.1047","volume":"8","author":"P Heudel","year":"2022","unstructured":"Heudel P, Frenel J-S, Dalban C, Bazan F, Joly F, Arnaud A et al (2022) Safety and efficacy of the mTOR inhibitor, Vistusertib, combined with Anastrozole in patients with hormone receptor\u2212positive recurrent or metastatic endometrial cancer. JAMA Oncol 8:1001. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1047","journal-title":"JAMA Oncol"},{"key":"56_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2025.04.004","author":"F Huang","year":"2025","unstructured":"Huang F, Li K, Shevach JW, Wang Q (2025) Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer. Journal of the National Cancer Center. https:\/\/doi.org\/10.1016\/j.jncc.2025.04.004","journal-title":"Journal of the National Cancer Center"},{"key":"56_CR49","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","volume":"2","author":"YH Ibrahim","year":"2012","unstructured":"Ibrahim YH, Garc\u00eda-Garc\u00eda C, Serra V, He L, Torres-Lockhart K, Prat A et al (2012) PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2:1036\u20131047. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0348","journal-title":"Cancer Discov"},{"key":"56_CR50","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA et al (2018) Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 15:222\u2013234. https:\/\/doi.org\/10.1038\/nrurol.2018.9","journal-title":"Nat Rev Urol"},{"key":"56_CR51","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","volume":"2","author":"A Juvekar","year":"2012","unstructured":"Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balma\u00f1\u00e0 J et al (2012) Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2:1048\u20131063. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0336","journal-title":"Cancer Discov"},{"key":"56_CR52","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6741","volume":"7","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA et al (2021) Effect of capivasertib in patients with an AKT1 E17K -mutated tumor. JAMA Oncol 7:271. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6741","journal-title":"JAMA Oncol"},{"key":"56_CR53","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32:5501\u20135511. https:\/\/doi.org\/10.1038\/onc.2013.206","journal-title":"Oncogene"},{"key":"56_CR54","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1158\/2159-8290.CD-11-0157","volume":"1","author":"M Keniry","year":"2011","unstructured":"Keniry M, Parsons R (2011) mTOR inhibition, the second generation: ATP-competitive mTOR inhibitor initiates unexpected receptor tyrosine kinase-driven feedback loop. Cancer Discov 1:203\u2013204. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0157","journal-title":"Cancer Discov"},{"key":"56_CR55","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","volume":"20","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI et al (2019) Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol 20:570\u2013580. https:\/\/doi.org\/10.1016\/S1470-2045(18)30905-7","journal-title":"Lancet Oncol"},{"key":"56_CR56","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(16)00106-6","volume":"17","author":"IE Krop","year":"2016","unstructured":"Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S et al (2016) Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 17:811\u2013821. https:\/\/doi.org\/10.1016\/S1470-2045(16)00106-6","journal-title":"Lancet Oncol"},{"key":"56_CR57","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/bjc.2013.530","volume":"109","author":"K Kruczek","year":"2013","unstructured":"Kruczek K, Ratterman M, Tolzien K, Sulo S, Lestingi TM, Nabhan C (2013) A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-na\u00efve castration-resistant prostate cancer. Br J Cancer 109:1711\u20131716. https:\/\/doi.org\/10.1038\/bjc.2013.530","journal-title":"Br J Cancer"},{"key":"56_CR58","doi-asserted-by":"publisher","DOI":"10.34133\/jbioxresearch.0057","author":"MR Kumbhare","year":"2025","unstructured":"Kumbhare MR, Chandak SM, Gode HS, Velhal SS, Ide BR, Shaikh AS et al (2025) Exploring capivasertib: a new AKT inhibitor for targeted cancer treatment. Journal of Bio-X Research. https:\/\/doi.org\/10.34133\/jbioxresearch.0057","journal-title":"Journal of Bio-X Research"},{"key":"56_CR59","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","volume":"76","author":"KJ Lastwika","year":"2016","unstructured":"Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR et al (2016) Control of PD-L1 expression by oncogenic activation of the AKT\u2013mTOR pathway in non-small cell lung cancer. Cancer Res 76:227\u2013238. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3362","journal-title":"Cancer Res"},{"key":"56_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15205047","author":"TK Le","year":"2023","unstructured":"Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L et al (2023) Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15205047","journal-title":"Cancers (Basel)"},{"key":"56_CR61","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14656566.2020.1825684","volume":"22","author":"N Lenze","year":"2021","unstructured":"Lenze N, Chera B, Sheth S (2021) An evaluation of buparlisib for the treatment of head and neck squamous cell carcinoma. Expert Opin Pharmacother 22:135\u2013144. https:\/\/doi.org\/10.1080\/14656566.2020.1825684","journal-title":"Expert Opin Pharmacother"},{"key":"56_CR62","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","volume":"23","author":"H Li","year":"2024","unstructured":"Li H, Wen X, Ren Y, Fan Z, Zhang J, He G et al (2024) Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions. Mol Cancer 23:164. https:\/\/doi.org\/10.1186\/s12943-024-02072-1","journal-title":"Mol Cancer"},{"key":"56_CR63","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-20-4131","volume":"27","author":"B Lim","year":"2021","unstructured":"Lim B, Potter DA, Salkeni MA, Silverman P, Haddad TC, Forget F et al (2021) Sapanisertib plus exemestane or fulvestrant in women with hormone receptor\u2013positive\/HER2-negative advanced or metastatic breast cancer. Clin Cancer Res 27:3329\u20133338. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4131","journal-title":"Clin Cancer Res"},{"key":"56_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq3802","author":"N Mao","year":"2025","unstructured":"Mao N, Lee YS, Salsabeel N, Zhang Z, Li D, Kaur H et al (2025) Uncoupling of Akt and mTOR signaling drives resistance to Akt inhibition in PTEN loss prostate cancers. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.adq3802","journal-title":"Sci Adv"},{"key":"56_CR65","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.eururo.2014.08.053","volume":"67","author":"RB Marques","year":"2015","unstructured":"Marques RB, Aghai A, de Ridder CMA, Stuurman D, Hoeben S, Boer A et al (2015) High Efficacy of Combination Therapy Using PI3K\/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models. Eur Urol 67:1177\u20131185. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.053","journal-title":"Eur Urol"},{"key":"56_CR66","doi-asserted-by":"publisher","first-page":"669","DOI":"10.14670\/HH-25.669","volume":"25","author":"AM Martelli","year":"2010","unstructured":"Martelli AM, Chiarini F, Evangelisti C, Grimaldi C, Ognibene A, Manzoli L et al (2010) The phosphatidylinositol 3-kinase\/AKT\/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histol Histopathol 25:669\u201380. https:\/\/doi.org\/10.14670\/HH-25.669","journal-title":"Histol Histopathol"},{"key":"56_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw562","author":"M Mart\u00edn","year":"2017","unstructured":"Mart\u00edn M, Chan A, Dirix L, O\u2019Shaughnessy J, Hegg R, Manikhas A et al (2017) A randomized adaptive phase II\/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2\u2013 advanced breast cancer (BELLE-4). Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdw562","journal-title":"Ann Oncol"},{"key":"56_CR68","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/bjc.2016.59","volume":"114","author":"J Mateo","year":"2016","unstructured":"Mateo J, Olmos D, Dumez H, Poondru S, Samberg NL, Barr S et al (2016) A first in man, dose-finding study of the mTORC1\/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. Br J Cancer 114:889\u2013896. https:\/\/doi.org\/10.1038\/bjc.2016.59","journal-title":"Br J Cancer"},{"key":"56_CR69","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/aps.2015.68","volume":"36","author":"L Meng","year":"2015","unstructured":"Meng L, Zheng XFS (2015) Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol Sin 36:1163\u20131169. https:\/\/doi.org\/10.1038\/aps.2015.68","journal-title":"Acta Pharmacol Sin"},{"key":"56_CR70","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1158\/1535-7163.MCT-14-1052","volume":"14","author":"DS Mortensen","year":"2015","unstructured":"Mortensen DS, Fultz KE, Xu S, Xu W, Packard G, Khambatta G et al (2015) CC-223, a potent and selective inhibitor of mTOR kinase. In vitro and in vivo characterization. Mol Cancer Ther 14:1295\u20131305. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-1052","journal-title":"Mol Cancer Ther"},{"key":"56_CR71","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1002\/cncr.26571","volume":"118","author":"S Moulder","year":"2012","unstructured":"Moulder S, Gladish G, Ensor J, Gonzalez-Angulo AM, Cristofanilli M, Murray JL et al (2012) A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer 118:2378\u20132384. https:\/\/doi.org\/10.1002\/cncr.26571","journal-title":"Cancer"},{"key":"56_CR72","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","volume":"27","author":"P Narayan","year":"2021","unstructured":"Narayan P, Prowell TM, Gao JJ, Fernandes LL, Li E, Jiang X et al (2021) FDA approval summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin Cancer Res 27:1842\u20131849. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3652","journal-title":"Clin Cancer Res"},{"key":"56_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/biom9040153","volume":"9","author":"A Papa","year":"2019","unstructured":"Papa A, Pandolfi PP (2019) The PTEN\u2013PI3K axis in cancer. Biomolecules 9:153. https:\/\/doi.org\/10.3390\/biom9040153","journal-title":"Biomolecules"},{"key":"56_CR74","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ygyno.2024.02.029","volume":"183","author":"A Passarelli","year":"2024","unstructured":"Passarelli A, Carbone V, Pignata S, Mazzeo R, Lorusso D, Scambia G et al (2024) Alpelisib for PIK3CA-mutated advanced gynecological cancers: first clues of clinical activity. Gynecol Oncol 183:61\u201367. https:\/\/doi.org\/10.1016\/j.ygyno.2024.02.029","journal-title":"Gynecol Oncol"},{"key":"56_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.819128","author":"Y Peng","year":"2022","unstructured":"Peng Y, Wang Y, Zhou C, Mei W, Zeng C (2022) PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.819128","journal-title":"Front Oncol"},{"key":"56_CR76","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.2217\/fon-2022-0045","volume":"18","author":"JA P\u00e9rez-Fidalgo","year":"2022","unstructured":"P\u00e9rez-Fidalgo JA, Criscitiello C, Carrasco E, Regan MM, Di Leo A, Ribi K et al (2022) A phase III trial of alpelisib + trastuzumab \u00b1 fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer. Future Oncol 18:2339\u20132349. https:\/\/doi.org\/10.2217\/fon-2022-0045","journal-title":"Future Oncol"},{"key":"56_CR77","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2021.39.15_suppl.2024","volume":"39","author":"SR Plotkin","year":"2021","unstructured":"Plotkin SR, Kumthekar P, Wen PY, Barker FG, Stemmer-Rachamimov A, Beauchamp RL et al (2021) Multi-center, single arm phase II study of the dual mTORC1\/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas. J Clin Oncol 39:2024\u20132024. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.2024","journal-title":"J Clin Oncol"},{"key":"56_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011088","volume":"22","author":"T Pungsrinont","year":"2021","unstructured":"Pungsrinont T, Kallenbach J, Baniahmad A (2021) Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistance-mediating mechanism to therapy of prostate cancer. Int J Mol Sci 22:11088. https:\/\/doi.org\/10.3390\/ijms222011088","journal-title":"Int J Mol Sci"},{"key":"56_CR79","doi-asserted-by":"publisher","first-page":"41976","DOI":"10.18632\/oncotarget.5659","volume":"6","author":"W Qi","year":"2015","unstructured":"Qi W, Morales C, Cooke LS, Johnson B, Somer B, Mahadevan D (2015) Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer. Oncotarget 6:41976\u201341987. https:\/\/doi.org\/10.18632\/oncotarget.5659","journal-title":"Oncotarget"},{"key":"56_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032289","volume":"24","author":"F Raith","year":"2023","unstructured":"Raith F, O\u2019Donovan DH, Lemos C, Politz O, Haendler B (2023) Addressing the reciprocal crosstalk between the AR and the PI3K\/AKT\/mTOR signaling pathways for prostate cancer treatment. Int J Mol Sci 24:2289. https:\/\/doi.org\/10.3390\/ijms24032289","journal-title":"Int J Mol Sci"},{"key":"56_CR81","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10:63\u201389. https:\/\/doi.org\/10.14740\/wjon1191","journal-title":"World J Oncol"},{"issue":"2","key":"56_CR82","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00280-018-3610-z","volume":"82","author":"J Rodon","year":"2018","unstructured":"Rodon J, P\u00e9rez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD et al (2018) Phase 1\/1b dose escalation and expansion study of BEZ235, a dual PI3K\/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemother Pharmacol 82(2):285\u2013298. https:\/\/doi.org\/10.1007\/s00280-018-3610-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"56_CR83","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3390\/biomedicines13061319","volume":"13","author":"AE Schmitz","year":"2025","unstructured":"Schmitz AE, Udgata S, Johnson KA, Deming DA (2025) The precision-guided use of PI3K pathway inhibitors for the treatment of solid malignancies. Biomedicines 13:1319. https:\/\/doi.org\/10.3390\/biomedicines13061319","journal-title":"Biomedicines"},{"key":"56_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1015-x","volume":"20","author":"P Sch\u00f6ffski","year":"2018","unstructured":"Sch\u00f6ffski P, Cresta S, Mayer IA, Wildiers H, Damian S, Gendreau S et al (2018) A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. Breast Cancer Res 20:109. https:\/\/doi.org\/10.1186\/s13058-018-1015-x","journal-title":"Breast Cancer Res"},{"key":"56_CR85","doi-asserted-by":"publisher","first-page":"OT3-09-01","DOI":"10.1158\/1538-7445.SABCS22-OT3-09-01","volume":"83","author":"E Shagisultanova","year":"2023","unstructured":"Shagisultanova E, Wisinski KB, Gawryletz CD, Datko FM, Medgyesy D, Diamond JR et al (2023) Abstract OT3-09-01: clinical trial of Alpelisib and Tucatinib in patients with PIK3CA-mutant HER2-positive metastatic breast cancer. Cancer Res 83:OT3-09-01-OT3-09-01. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-OT3-09-01","journal-title":"Cancer Res"},{"key":"56_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124507","volume":"21","author":"BY Shorning","year":"2020","unstructured":"Shorning BY, Dass MS, Smalley MJ, Pearson HB (2020) The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci 21:4507. https:\/\/doi.org\/10.3390\/ijms21124507","journal-title":"Int J Mol Sci"},{"key":"56_CR87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS6090","volume":"39","author":"D Soulieres","year":"2021","unstructured":"Soulieres D, Faivre SJ, Dreyer K, Licitra LF (2021) The BURAN study of buparlisib (AN2025) in combination with paclitaxel compared to paclitaxel alone, in patients with recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol 39:TPS6090\u2013TPS6090. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS6090","journal-title":"J Clin Oncol"},{"key":"56_CR88","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/1878-0261.13577","volume":"18","author":"T Sugawara","year":"2024","unstructured":"Sugawara T, Nevedomskaya E, Heller S, B\u00f6hme A, Lesche R, von Ahsen O et al (2024) Dual targeting of the androgen receptor and <scp>PI3K<\/scp> \/ <scp>AKT<\/scp> \/ <scp>mTOR<\/scp> pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis. Mol Oncol 18:726\u2013742. https:\/\/doi.org\/10.1002\/1878-0261.13577","journal-title":"Mol Oncol"},{"key":"56_CR89","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S et al (2021) Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 398:131\u2013142. https:\/\/doi.org\/10.1016\/S0140-6736(21)00580-8","journal-title":"Lancet"},{"key":"56_CR90","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2013.03.040","volume":"64","author":"AJ Templeton","year":"2013","unstructured":"Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, B\u00e4rtschi D, Dr\u00f6ge C et al (2013) Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08\/08). Eur Urol 64:150\u2013158. https:\/\/doi.org\/10.1016\/j.eururo.2013.03.040","journal-title":"Eur Urol"},{"key":"56_CR91","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1200\/JCO.2024.42.16_suppl.3092","volume":"42","author":"DM Thomas","year":"2024","unstructured":"Thomas DM, Daniele G, Kim JE, Gadgeel SM, Ahn ER, Paz-Ares LG et al (2024) Ipatasertib in patients with AKT1\/2\/3 mutation-positive (AKT mut) tumors: TAPISTRY study. J Clin Oncol 42:3092\u20133092. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3092","journal-title":"J Clin Oncol"},{"key":"56_CR92","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe LM, Yuzugullu H, Zhao JJ (2015) PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 15:7\u201324. https:\/\/doi.org\/10.1038\/nrc3860","journal-title":"Nat Rev Cancer"},{"key":"56_CR93","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12282-024-01640-z","volume":"32","author":"E Tokunaga","year":"2025","unstructured":"Tokunaga E, Iwata H, Itoh M, Taira T, Toyama T, Mizuno T et al (2025) Capivasertib and fulvestrant for patients with HR-positive\/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial. Breast Cancer 32:132\u2013143. https:\/\/doi.org\/10.1007\/s12282-024-01640-z","journal-title":"Breast Cancer"},{"key":"56_CR94","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.3892\/ijo.2014.2601","volume":"45","author":"P Toren","year":"2014","unstructured":"Toren P, Zoubeidi A (2014) Targeting the PI3K\/Akt pathway in prostate cancer: challenges and opportunities (Review). Int J Oncol 45:1793\u20131801. https:\/\/doi.org\/10.3892\/ijo.2014.2601","journal-title":"Int J Oncol"},{"key":"56_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112342","volume":"9","author":"DJ Turnham","year":"2020","unstructured":"Turnham DJ, Bullock N, Dass MS, Staffurth JN, Pearson HB (2020) The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells 9:2342. https:\/\/doi.org\/10.3390\/cells9112342","journal-title":"Cells"},{"key":"56_CR96","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1128\/MCB.24.3.1007-1021.2004","volume":"24","author":"KM Vasudevan","year":"2004","unstructured":"Vasudevan KM, Gurumurthy S, Rangnekar VM (2004) Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 24:1007\u20131021. https:\/\/doi.org\/10.1128\/MCB.24.3.1007-1021.2004","journal-title":"Mol Cell Biol"},{"key":"56_CR97","first-page":"5430","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang Y, Dai B (2015) PTEN genomic deletion defines favorable prognostic biomarkers in localized prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med 8:5430\u20135437","journal-title":"Int J Clin Exp Med"},{"key":"56_CR98","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1093\/advances\/nmac055","volume":"13","author":"G Wang","year":"2022","unstructured":"Wang G, Chen L, Qin S, Zhang T, Yao J, Yi Y et al (2022) Mechanistic target of rapamycin complex 1: from a nutrient sensor to a key regulator of metabolism and health. Adv Nutr 13:1882\u20131900. https:\/\/doi.org\/10.1093\/advances\/nmac055","journal-title":"Adv Nutr"},{"key":"56_CR99","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15:701\u2013711. https:\/\/doi.org\/10.1038\/nrc4016","journal-title":"Nat Rev Cancer"},{"key":"56_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.875372","author":"X Wu","year":"2022","unstructured":"Wu X, Xu Y, Liang Q, Yang X, Huang J, Wang J et al (2022) Recent advances in dual PI3K\/mTOR inhibitors for tumour treatment. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.875372","journal-title":"Front Pharmacol"},{"key":"56_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115676","volume":"168","author":"M Wyla\u017a","year":"2023","unstructured":"Wyla\u017a M, Kaczmarska A, Pajor D, Hryniewicki M, Gil D, Duli\u0144ska-Litewka J (2023) Exploring the role of PI3K\/AKT\/mTOR inhibitors in hormone-related cancers: a focus on breast and prostate cancer. Biomed Pharmacother 168:115676. https:\/\/doi.org\/10.1016\/j.biopha.2023.115676","journal-title":"Biomed Pharmacother"},{"key":"56_CR102","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1158\/2159-8290.CD-20-0163","volume":"10","author":"TA Yap","year":"2020","unstructured":"Yap TA, Kristeleit R, Michalarea V, Pettitt SJ, Lim JSJ, Carreira S et al (2020) Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1\/2 - and non\u2013 BRCA1\/2 -mutant cancers. Cancer Discov 10:1528\u20131543. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0163","journal-title":"Cancer Discov"},{"key":"56_CR103","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","volume":"30","author":"DA Yardley","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M et al (2013) Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30:870\u2013884. https:\/\/doi.org\/10.1007\/s12325-013-0060-1","journal-title":"Adv Ther"},{"key":"56_CR104","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou Z, Tao T, Li H, Zhu X (2020) mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci 10:31. https:\/\/doi.org\/10.1186\/s13578-020-00396-1","journal-title":"Cell Biosci"}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-025-00056-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44446-025-00056-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44446-025-00056-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:31:31Z","timestamp":1772739091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44446-025-00056-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["56"],"URL":"https:\/\/doi.org\/10.1007\/s44446-025-00056-w","relation":{},"ISSN":["1319-0164","2213-7475"],"issn-type":[{"value":"1319-0164","type":"print"},{"value":"2213-7475","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report there are no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"2"}}